Evidence map›Paper›PMID 23637027›Full record

ArticleCurrent treatment options in neurology2013

Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis.

Nikolai Pfender, Riccardo Saccardi, Roland Martin

Abstract read
PubMed Publisher
In one paragraph

Article in Current treatment options in neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Review
  3. Genetically modified hematopoietic stem/progenitor cells that produce IL-10-secreting regulatory T cells.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  4. Review
  5. Article
  6. Review
  7. Therapeutic management of severe relapses in multiple sclerosis.Current treatment options in neurology · 2015
    Article
  8. Article
  9. Review
  10. Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT.Annals of clinical and translational neurology · 2014
    Article
  11. Article
  12. Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS.Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nikolai PfenderNeuroimmunology and MS Research, Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland.
Riccardo Saccardi
Roland Martin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementDespite the development of several injectable or oral treatments for relapsing-remitting multiple sclerosis (RRMS), it remains difficult to treat patients with aggressive disease, and many of these continue to develop severe disability. During the last two decades autologous hematopoietic stem cell transplantation (aHSCT) has been explored with the goal to eliminate an aberrant immune system and then re-install a healthy and tolerant one from hematopoietic precursor cells that had been harvested from the patient prior to chemotherapy. Clinical studies have shown that aHSCT is able to completely halt disease activity in the majority of patients with aggressive RRMS. Research on the mechanisms of action supports that aHSCT indeed leads to renewal of a healthy immune system. Below we will summarize important aspects of aHSCT and mention the currently best-examined regimen.

Identifiers

PMID23637027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.